DOCSLIB.ORG

2006 Pharmaceuticals Sector

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2006 Pharmaceuticals Sector Claremont McKenna College Roberts Environmental Center 2006 Roberts Environmental Center Pacific Sustainability Index Scores Pharmaceuticals Sector J. Emil Morhardt Elgeritte Adidjaja Holly E. Allen-Young William M. Ellison Claire Fowler Esbenshade Christopher David Frantz Kira Elizabeth Gaza Ina Hanna Labermeier Emery L. Mitchem James H. Vanden Bos Elliott Vander Kolk Price: $20.00 Claremont McKenna College Roberts Environmental Center Contents Page Publications from Roberts Environmental Center The Roberts Environmental Center publishes analyses of Company Rankings 3 corporate environmental and social reports—together called sustainability reports—on the web and in special The Pacific Sustainability Index in a Nutshell 4 reports. Visual Cluster Analysis 5 We also write books about environmental and sustainability reporting, the first of which is Clean, Green, Environmental Intent Element of the PSI Scores 6 and Read All Over: Ten Rules for Corporate Environmental and Sustainability Reporting, available Environmental Reporting Element of the PSI Scores 7 from ASQ Press, and publish articles in academic technical journals. Social Intent Element of the PSI Scores 8 Existing sector reports available online at Social Reporting Element of the PSI Scores 9 www.roberts.mckenna.edu: Environmental Scores Ranking 10 2006 Pharmaceuticals 2006 Chemicals Social Scores Ranking 11 2006 Electronics, Semiconductor, and Peripherals 2006 Metals, Mining, and Crude Oil Production Use of Environmental Indicators 12 2006 Colleges and Universities 2005 Forest and Paper Products Use of Social Indicators 13 2005 Consumer Food, Food Production, and Beverages 2005 Energy and Utilities Relationship between overall PSI Score and 14 2004 Motor Vehicles and Parts Companies' Economic Indicators 2004 Petroleum Refining 2004 Electronics Use of Voluntary Guidelines and Partnerships 16 2004 Chemicals 2004 Pharmaceuticals Analysts’ Comments, alphabetically listed by 17 company name To order printed copies of this report, please contact: Roberts Environmental Center, Claremont McKenna 22 Dr. J. Emil Morhardt, Director College, and The Claremont Colleges Roberts Environmental Center Claremont McKenna College 925 N. Mills Avenue Claremont, CA 91711-5916 USA 909-621-8190, Fax 909-607-1185 [email protected] Front Cover Photo: Joint Science Department Biology Lab (REC) The goal of corporate report analysis conducted by the Roberts Environmental Center is to acquaint students with environmental and social issues facing the world’s industries, and the ways in which industry approaches and resolves these issues. The data presented in this report were collected by student research assistants and a research fellow at the Roberts Environmental Center. Copyright 2006 © by J. Emil Morhardt. All rights reserved. www.roberts.mckenna.edu 2006 Roberts Environmental Center Pharmaceuticals Industry Report 2 Claremont McKenna College Roberts Environmental Center 2005 Fortune Global 500 and Fortune 1000 Pharmaceuticals Corporate Environmental and Sustainability Reporting During the past decade, large corporations have begun to report voluntarily on the PSI Overall Grading environmental issues affecting their companies and on how they deal with them. The addition of social issues to these reports has resulted in some firms designating them sustainability reports. A+ Bristol-Myers Squibb (U.S.) Some firms produce these reports yearly, others only occasionally, and some not at all. We A Abbott Laboratories (U.S.) obtain these reports and any additional information exclusively from corporate web sites. A- AstraZeneca (Britain) This report covers the largest 30 companies in the Pharmaceuticals sectors of the 2005 Fortune Global 500 and the Fortune 1000 lists, whether or not they produced formal environmental A- Johnson and Johnson (U.S.) or sustainability reports. It is based on all environmental and social information available on their A- Pfizer (U.S.) web sites during the period of our analysis. After we finished analyzing the companies' reports, B+ Eli Lilly (U.S.) we provided a draft sector report online to allow companies to review their score and provide comments. The quality of the environmental and social reporting was characterized by students B+ GlaxoSmithKline (Britain) at the Claremont Colleges using the Roberts Environmental Center’s Pacific Sustainability Index B Novartis (Switzerland) (PSI). B Roche Group (Switzerland) Analysis period: 10/20/2005 through 12/6/2005 B Allergan (U.S.) Draft sector report available for review: 3/30/2006 through 5/1/2006 B Sanofi-Aventis (France) Pharmaceuticals B Merck (U.S.) B- Wyeth (U.S.) Company PSI Rankings C+ Schering-Plough Corporation Bristol-Myers Squibb (U.S.) Abbott Laboratories C+ Amgen (U.S.) AstraZeneca D+ Genzyme (U.S.) Johnson and Johnson D Gilead Sciences (U.S.) During the past decade,Pfizer large corporations have begun affecting their companiesEli Lilly and on how they deal with them. D Chiron (U.S.) The addition GlaxoSmithKlineof social issues to these reports has resulted in some firms designating them “sustainability reports.” D Forest Laboratories (U.S.) Novartis Some firms produce these reports yearly, others only D IVAX (Teva Pharmaceutical) occasionally, andRoche some Group not at all. We obtain these reports and any additional informationAllergan exclusively from corporate (Israel) web sites. Sanofi-Aventis D- Watson Pharmaceuticals This report covers all ofMerck the companies in the energy and (U.S.) utilities sectors of the 2005 Fortune Global 500 and all Wyeth energy companies from the Fortune 1000 list, whether or D- Biogen Idec Inc. (U.S.) Schering-Plough Corporation not they produced formal environmental or sustainability D- NBTY (U.S.) reports. It is based onAmgen all environmental and social information availableGenzyme on their web sites during the period of D- Mylan Laboratories (U.S.) our analysis fromGilead October Sciences 20, 2004 through April 18, 2005, D- King Pharmaceuticals (U.S.) including annual reportsChiron and, for American companies, 10- K forms. We extended the period of our analysis by incorporatingForest feedbacks Laboratories received from companies from MayIVAX 20,2005 (Teva Pharmaceutical)through June 15, 2005. The quality of the environmentalW atson Pharmaceuticals and social reporting was characterized by students at theBiogen Claremont Idec Inc. Colleges using the Roberts Environmental Center’sNBTY Pacific Sustainability Index (PSI). Mylan Laboratories King Pharmaceuticals 0 255075100 www.roberts.mckenna.edu 2006 Roberts Environmental Center Pharmaceuticals Industry Report 3 Claremont McKenna College Roberts Environmental Center The Pacific Sustainability Index (PSI) in a Nutshell* The PSI Scoring System What do we mean by performance? The Pacific Sustainability Index (PSI) uses two systematic Topics analyzed in the reporting and performance categories are questionnaires to analyze the quality of the sustainability reporting—a identical. The performance category is used to measure the performance base questionnaire for reports across sectors and a sector-specific of the reported environmental performance (EP) or social performance questionnaire for companies within the same sector. The selection of (SP) indicators. The maximum score for each topic in the performance questions is based on the most frequently-mentioned topics in over 500 category is two points: corporate sustainability reports analyzed from 2002 through mid-2005 at the Roberts Environmental Center. - Quantitative topics get one point if there is a positive data trend and another point if data are shown to be better than peer average. An The philosophy of the PSI is described in detail in our book, Clean, additional point is awarded if the company is clearly taking a leadership Green, and Read All Over published by and available from the American position for the sector, or if the data are at maximum performance (e.g. Society for Quality Press**. The selection of PSI topics is constantly 100% recycling rate, 0 emissions, 0 injuries). adapted to include topics discussed in the world’s best sustainability reports, raising the bar for better sustainability reporting in the future. - Qualitative topics get one point if there is a discussion on the benefits or advantages from the program, another point if the program is continuously being monitored or improved by the company and another How do we collect our data? when the company is a leader or role model as evidenced by external recognition or awards. Relevant English web pages are downloaded from the main corporate website for analysis. Our scoring excludes data independently stored - Philosophical topics get one point if the company subscribes to at outside the main corporate web site. When a corporate subsidiary has least one internal or external social program that deals with a particular its own sustainability reporting, partial credit is given to the parent issue (e.g. Company's own code of conduct or Global Compact), another company when a direct link is provided in the main corporate web site. point when there is an active (action required) program or policy the company uses to enforce this principle such as a compliance mechanism, zero-tolerance ruling for non-compliance, external auditor, whistleblower What does the score mean? program, certification program, etc., and another point if the company Although our scoring uses a uniform scoring guideline, analysts’ explicitly states that these guidelines or principles are being followed. subjectivity plays
Load more

Recommended publications
  • Biocentury 8.15.16
    WEEK OF AUGUST 15, 2016 6 PRODUCT DEVELOPMENT: NO ANTIGEN LEFT BEHIND Amgen has added to its immuno-oncology arsenal with its deal for Advaxis’ pan- epitope neoantigen vaccine platform. SERVING RETURNS 9 EMERGING COMPANY PROFILE: RESTRAINING TRANSLATION BY STEVE EDELSON, SENIOR EDITOR Bantam is developing small molecule eIF4E inhibitors to treat a range of cancers, China’s Ally Bridge Group hit the investment world’s starting with B cell malignancies. radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with REGULATION: the listing of WuXi’s biologics unit in Hong Kong this 10 year, the question is what will be its next moves to ADAPTING FOR THE REAL WORLD generate outsized returns for its investors. EMA says better strategies for real-world evidence and more patient and payer involvement are necessary Ally Bridge, which has a about $1.5 billion under next steps for its adaptive pathway initiative. management across three funds and an international base of LPs, thinks its returns and continued visibility will come from a handful of public and private portfolio companies with transformative data events, the first of EBB & FLOW: 13 which should come this half. LION’S SHARE OF THE WORK Aslan’s validating event. Plus: Cutting a check The firm also says it is working on new private equity to Cleave; and Ironwood’s operating leverage. deals that will rival WuXi in terms of size and impact. Ally Bridge is keeping its private equity plans under wraps, and does not disclose names of investments in its Asia hedge fund.
    [Show full text]
  • Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc
    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Gathering Momentum Company Overview Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant’s primary focus is principally in the areas of dermatology and neurology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in dermatology and neurology. Valeant plans to strategically expand its pipeline by adding new compounds or products through product or company acquisitions and will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Valeant’s strategic markets are primarily in the United States, Canada, Central and Eastern Europe, Latin America, Australia and South East Asia. Headquartered in Montreal, Quebec, Valeant has approximately 7,000 employees worldwide. FORWARD-LOOKING Statements In addition to current and historical information, this Annual Report contains forward-looking statements, including, without limitation, statements regarding our strategy, expected future revenue, the prospects for approval of product candidates and the timing of regulatory approvals, and the growth and future development of the company, its business units and its products. Words such as “expects,” “anticipates,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” or similar language identify forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties. Our actual results may differ materially from those contemplated by the forward-looking statements.
    [Show full text]
  • FDA Listing of Authorized Generics As of July 1, 2021
    FDA Listing of Authorized Generics as of July 1, 2021 Note: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs). Because the annual reports seldom indicate the date an AG initially entered the market, the column headed “Date Authorized Generic Entered Market” reflects the period covered by the annual report in which the AG was first reported. Subsequent marketing dates by the same firm or other firms are not included in this listing. As noted, in many cases FDA does not have information on whether the AG is still marketed and, if not still marketed, the date marketing ceased. Although attempts have been made to ensure that this list is as accurate as possible, given the volume of d ata reviewed and the possibility of database limitations or errors, users of this list are cautioned to independently verify the information on the list. We welcome comments on and suggested changes (e.g., additions and deletions) to the list, but the list may include only information that is included in an annual report. Please send suggested changes to the list, along with any supporting documentation to: [email protected] A B C D E F G H I J K L M N O P Q R S T U V X Y Z NDA Applicant Date Authorized Generic Proprietary Name Dosage Form Strength Name Entered the Market 1 ACANYA Gel 1.2% / 2.5% Bausch Health 07/2018 Americas, Inc.
    [Show full text]
  • 11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
    [Show full text]
  • Malek V. Abbvie, Inc. Et
    Case 1:20-cv-07492-LJL Document 1 Filed 09/12/20 Page 1 of 73 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK RICHARD MALEK, on his own behalf and all others similarly situated, Civil Action No. __________ Plaintiff, v. CLASS ACTION COMPLAINT ABBVIE INC., ALLERGAN, INC., ALLERGAN SALES, LLC, ALLERGAN USA, DEMAND FOR JURY TRIAL INC., FOREST LABORATORIES, INC., FOREST LABORATORIES HOLDINGS, LTD., FOREST LABORATORIES IRELAND, LTD., and FOREST LABORATORIES, LLC, Defendants. Plaintiff Richard Malek (“Plaintiff”), on behalf of himself and all others similarly situated, brings this Class Action Complaint against AbbVie, Inc. (“AbbVie”); Allergan, Inc., Allergan Sales, LLC, and Allergan USA, Inc. (collectively, “Allergan”); and Forest Laboratories, Inc., Forest Laboratories Holdings, Ltd., Forest Laboratories, LLC, and Forest Laboratories Ireland Ltd. (collectively, “Forest”) (together with AbbVie and Allergan, “Defendants”) for Defendants’ violations of federal and state antitrust, consumer protection and unjust enrichment laws concerning the pharmaceutical drug Bystolic® (nebivolol hydrochloride) (“Bystolic”). Based upon the investigation of counsel, information and belief, and personal knowledge, Plaintiff alleges as follows: 1 CLASS ACTION COMPLAINT Case 1:20-cv-07492-LJL Document 1 Filed 09/12/20 Page 2 of 73 INTRODUCTION 1. This is an antitrust action seeking treble damages and declaratory and injunctive relief under state antitrust, consumer protection and unjust enrichment law, and federal antitrust law, as a result of Defendants’ unlawful exclusion of generic substitutes for the branded drug Bystolic. Bystolic contains the active pharmaceutical ingredient nebivolol hydrochloride or nebivolol HCl and is an important cardiovascular prescription drug used to treat high blood pressure. It is commonly referred to as a “beta blocker” or a beta-adrenergic blocking agent that reduces blood pressure.
    [Show full text]
  • Rebateable Manufacturers
    Rebateable Labelers – July 2021 Manufacturers are responsible for updating their eligible drugs and pricing with CMS. Montana Healthcare Programs will not pay for an NDC not updated with CMS. Note: Some manufacturers on this list may have some NDCs that are covered and others that are not. Manufacturer ID Manufacturer Name 00002 ELI LILLY AND COMPANY 00003 E.R. SQUIBB & SONS, LLC. 00004 HOFFMANN-LA ROCHE 00006 MERCK & CO., INC. 00007 GLAXOSMITHKLINE 00008 WYETH PHARMACEUTICALS LLC, 00009 PHARMACIA AND UPJOHN COMPANY LLC 00013 PFIZER LABORATORIES DIV PFIZER INC 00015 MEAD JOHNSON AND COMPANY 00023 ALLERGAN INC 00024 SANOFI-AVENTIS, US LLC 00025 PFIZER LABORATORIES DIV PFIZER INC 00026 BAYER HEALTHCARE LLC 00032 ABBVIE INC. 00037 MEDA PHARMACEUTICALS, INC. 00039 SANOFI-AVENTIS, US LLC 00046 WYETH PHARMACEUTICALS INC. 00049 ROERIG 00051 ABBVIE INC 00052 ORGANON USA INC. 00053 CSL BEHRING L.L.C. 00054 HIKMA PHARMACEUTICAL USA, INC. 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00065 ALCON LABORATORIES, INC. 00068 AVENTIS PHARMACEUTICALS 00069 PFIZER LABORATORIES DIV PFIZER INC 00071 PARKE-DAVIS DIV OF PFIZER 00074 ABBVIE INC 00075 AVENTIS PHARMACEUTICALS, INC. 00078 NOVARTIS 00085 SCHERING CORPORATION 00087 BRISTOL-MYERS SQUIBB COMPANY 00088 AVENTIS PHARMACEUTICALS 00093 TEVA PHARMACEUTICALS USA, INC. 00095 BAUSCH HEALTH US, LLC Page 1 of 19 Manufacturer ID Manufacturer Name 00096 PERSON & COVEY, INC. 00113 L. PERRIGO COMPANY 00115 IMPAX GENERICS 00116 XTTRIUM LABORATORIES, INC. 00121 PHARMACEUTICAL ASSOCIATES, INC. 00131 UCB, INC. 00132 C B FLEET COMPANY INC 00143 HIKMA PHARMACEUTICAL USA, INC. 00145 STIEFEL LABORATORIES, INC, 00168 E FOUGERA AND CO. 00169 NOVO NORDISK, INC. 00172 TEVA PHARMACEUTICALS USA, INC 00173 GLAXOSMITHKLINE 00178 MISSION PHARMACAL COMPANY 00185 EON LABS, INC.
    [Show full text]
  • Important Transaction and Tax Information Regarding the Exchange Transaction of Pharmaceutical Holdrs Trust Into Shares of Market Vectors Pharmaceutical Etf
    IMPORTANT TRANSACTION AND TAX INFORMATION REGARDING THE EXCHANGE TRANSACTION OF PHARMACEUTICAL HOLDRS TRUST INTO SHARES OF MARKET VECTORS PHARMACEUTICAL ETF For electing owners (“Exchange Participants”) of Pharmaceutical HOLDRS Trust (“PPH HOLDRS”), units of PPH HOLDRS were exchanged on December 20, 2011 for shares of Market Vectors Pharmaceutical ETF. For each PPH HOLDR receipt validly tendered, Exchange Participants received 1 share of Market Vectors Pharmaceutical ETF. This exchange was effected through a series of transfers and rebalance transactions (sales transactions in certain securities underlying the PPH HOLDRS and purchase transactions in new securities for exchange into Market Vectors Pharmaceutical ETF). These transactions were authorized by the Exchange Participant and executed on their behalf. As a result of the rebalance transactions, part of this exchange may result in a taxable event and cost basis adjustments to the Exchange Participant. Provided is a breakdown of the exchange transactions and tax implications based on a ‘PPH HOLDR trading unit” (100 PPH HOLDRS receipts) 1. For each PPH HOLDR Trading Unit tendered, BNY Mellon Shareowner Services as Exchange Agent for the exchange offer, delivered the following securities per PPH HOLDR Trading Unit to BNY ConvergEx Execution Solutions LLC (“ConvergEx”), acting in its capacity transition manager in connection with the exchange offer. The total value of these securities transferred per PPH HOLDR Trading Unit, based on the December 20, 2011 market close, was $7,191.63.
    [Show full text]
  • Merck & Co., Inc
    As filed with the Securities and Exchange Commission on February 28, 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 _________________________________ FORM 10-K (MARK ONE) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2016 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 1-6571 _________________________________ Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth, N. J. 07033 (908) 740-4000 Incorporated in New Jersey I.R.S. Employer Identification No. 22-1918501 Securities Registered pursuant to Section 12(b) of the Act: Name of Each Exchange Title of Each Class on which Registered Common Stock ($0.50 par value) New York Stock Exchange 1.125% Notes due 2021 New York Stock Exchange 0.500% Notes due 2024 New York Stock Exchange 1.875% Notes due 2026 New York Stock Exchange 2.500% Notes due 2034 New York Stock Exchange 1.375% Notes due 2036 New York Stock Exchange Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2017: 2,745,571,067. Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 30, 2016 based on closing price on June 30, 2016: $159,263,000,000. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
    [Show full text]
  • Milnacipran Hcl) Tablets Prior to Initiating Treatment with Savella and Periodically Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION have been reported with SNRIs and SSRIs. Discontinue Savella These highlights do not include all the information needed to and initiate supportive treatment (5.2, 7). use Savella safely and effectively. See full prescribing Elevated blood pressure and heart rate: Cases have been information for Savella. reported with Savella. Monitor blood pressure and heart rate SAVELLA® (milnacipran HCl) Tablets prior to initiating treatment with Savella and periodically Initial U.S. Approval: 2009 throughout treatment (5.3, 5.4). Seizures: Cases have been reported with Savella therapy. WARNING: SUICIDALITY AND ANTIDEPRESSANT Prescribe Savella with care in patients with a history of seizure DRUGS disorder (5.5). See full prescribing information for complete boxed warning. Hepatotoxicity: More patients treated with Savella than with placebo experienced mild elevations of ALT and AST. Rarely, Increased risk of suicidal ideation, thinking, and behavior fulminant hepatitis has been reported in patients treated with in children, adolescents, and young adults taking Savella. Avoid concomitant use of Savella in patients with antidepressants for major depressive disorder (MDD) and substantial alcohol use or chronic liver disease (5.6). other psychiatric disorders. Savella is not approved for use Discontinuation: Withdrawal symptoms have been reported in in pediatric patients (5.1). patients when discontinuing treatment with Savella. A gradual dose reduction is recommended (5.7). ---------------------INDICATIONS AND USAGE--------------------- Abnormal Bleeding: Savella may increase the risk of bleeding Savella® is a selective serotonin and norepinephrine reuptake events. Caution patients about the risk of bleeding associated inhibitor (SNRI) indicated for the management of fibromyalgia (1). with the concomitant use of Savella and NSAIDs, aspirin, or Savella is not approved for use in pediatric patients (5.1).
    [Show full text]
  • Sitting Down with Christian Schneider, Director Of
    APRIL 2016 # 18 Upfront In My View Business Sitting Down With Reducing the manufacturing Why pharma must address Can small biotechs bear the Christian Schneider, costs of gene therapies environmental discharges burden of innovation? Director of NIBSC 10 17 48 – 49 50 – 51 www.themedicinemaker.com We’re Backing Batch Pharma is investing in continuous manufacturing for the future, but batch-based processing is the here and now! From powder to coated tablet and from R&D to full-scale Designed with integration in mind, you can select from a variety manufacturing, no other supplier offers such a comprehensive of standard process modules to suit your project needs. Plus, as range of batch-based technologies for oral solid dosage form containment experts, we not only offer the largest portfolio of production. Whatever your application, no matter how contained processing solutions, we can assist with the selection challenging, GEA’s powder handling, granulating, drying, process and optimise your entire production line, making it compression and coating solutions will meet and exceed efficient, safe and cost-effective. Contact [email protected] your individual requirements. today for more information or talk to an expert at POWTECH (booth 3A-237) or INTERPHEX (booth 2421). gea_batch_ad_medicine_maker.indd 2 24/03/2016 15:00 Online this Month Controlling Crystallization lecturer in the Department of Chemical Engineering at Imperial College London, We all know that crystallization is crucial UK, and focuses on understanding the in the pharma industry when it comes role of surface properties in particle to manufacturing active pharmaceutical engineering. Recently, he has examined ingredients (APIs) – and on page 12 of the feasibility of establishing template- We’re Backing Batch this issue you can read a snapshot about induced polymorphic domains for API the fascinating work from Jerry Heng crystallization.
    [Show full text]
  • Policy & Practice
    DECEMBER 2010 • WWW.ECARDIOLOGYNEWS.COM PRACTICE TRENDS 47 POLICY & PRACTICE depressant Paxil CR, the diabetes med- enue, costs, and staffing and found that ication Avandamet, and the anti-infection it correlated with $50,000 more net rev- WANT MORE HEALTH REFORM NEWS? ointment Bactroban. The complaint al- enue per full-time physician in practices SUBSCRIBE TO OUR PODCAST – SEARCH leged that the drugmaker failed to prove that were not owned by hospitals or in- ‘POLICY & PRACTICE’ IN THE ITUNES STORE that Bactroban and Kytril were not con- tegrated delivery systems. The wired taminated with microorganisms. practices reported $105,591 higher ex- AHA Merges Guidelines compared with only 58 men per 1,000 ad- GlaxoSmithKline will pay the federal penses per full-time physician, but had The American Heart Association has missions. The data come from the government $600 million, and a whistle- significantly more revenue per physi- combined its quality improvement pro- agency’s Trends in Hospital Risk-Adjust- blower will receive $96 million for hav- cian, the association said. “These data in- grams on cardiopulmonary resuscita- ed Mortality for Selected Diagnoses by Pa- ing tipped the federal government to dicate that there are financial benefits to tion and postresuscitation care. The tient Subgroups, 2000-2007. the manufacturing issues. The states are practices that implement an EHR sys- melding of the association’s National eligible to receive up to $163 million tem,” Dr. William Jessee, the associa- Registry of CardioPulmonary Resusci- Red Flag for A Fib Drug from GSK. The complaint alleged that tion’s president and CEO, said in a state- tation program with its Get With the The Institute for Safe Medication Practices the company knowingly caused false ment.
    [Show full text]
  • Biopharma Boom Fosters Deal Spree
    Biopharma boom fosters deal spree Valuations and volume are up in a buoyant year for biopharmaceutical dealmaking. From tax inversions to gene therapy and, of course, immuno-oncology, 2014 and early 2015 featured plenty of wheeling and dealing. BY CHRIS MORRISON Table 1. Top 10 acquisitions announced in 2014. lthough it was a record year for biophar- Deal Value maceutical dealmaking—a year that A included more than $200 billion worth Actavis acquires Allergan $66 billion of mergers and acquisitions—one could argue Actavis acquires Forest Laboratories $22.8 billion that the most interesting and dramatic deals reportsBCIQ; Company of 2014 were the ones that never happened. Merck & Co. acquires Cubist Pharmaceuticals $9.5 billion Those almost-deals, mega-mergers in hot pur- Roche acquires Intermune $8.3 billion suit of corporate-friendly tax climates to drive margin expansion of the combined entities, Mallinckrodt acquires Questcor $5.7 billion were eventually thwarted by recalcitrant targets Merck & Co. acquires Idenix $3.7 billion or the slow-to-materialize posturing of the US Treasury. They were massive and oxygen con- Otsuka acquires Avanir $3.5 billion suming, and their failures set up rebound deals that, though smaller, are no less intriguing. Forest Laboratories acquires Aptalis $2.9 billion The failed $117 billion and $53 billion Endo acquires Auxilium $2.6 billion takeovers of AstraZeneca by Pfizer and Shire by AbbVie, respectively, tell only part of the Johnson & Johnson acquires Alios $1.75 billion story of 2014’s massive dealmaking binge. Data courtesy of Biocentury’s BCIQ Database. All acquisitions are of biopharma companies with patented prescription pharmaceutical focus (excludes devices, diagnostics, OTC, generic-only deals).
    [Show full text]